

Published in final edited form as:

*Am J Manag Care*. 2011 October ; 17(10): 693–700.

## Routine Pre-cesarean *Staphylococcus aureus* Screening and Decolonization: A Cost-Effectiveness Analysis

Bruce Y. Lee, MD, MBA, Ann E. Wiringa, MPH, Elizabeth A. Mitgang, Sarah M. McGlone, MPH, Abena N. Afriyie, BS, Yeohan Song, BS, and Richard H. Beigi, MD, MSc

Public Health Computational and Operations Research, University of Pittsburgh School of Medicine and Graduate School of Public Health (BYL, AEW, EAM, SMM, ANA, YS), Pittsburgh, PA; Division of Reproductive Infectious Diseases, Magee-Womens Hospital of the University of Pittsburgh Medical Center (RHB), Pittsburgh, PA.

### Abstract

**Objectives**—To estimate the economic value of screening pregnant women for *Staphylococcus aureus* carriage before cesarean delivery.

**Study Design**—Computer simulation model.

**Methods**—We used computer simulation to assess the cost-effectiveness, from the third-party payer perspective, of routine screening for *S aureus* (and subsequent decolonization of carriers) before planned cesarean delivery. Sensitivity analyses explored the effects of varying *S aureus* colonization prevalence, decolonization treatment success rate (for the extent of the puerperal period), and the laboratory technique (agar culture vs polymerase chain reaction [PCR]) utilized for screening and pathogen identification from wound isolates.

**Results**—Pre-cesarean screening and decolonization were only cost-effective when agar was used for both screening and wound cultures when the probability of decolonization success was 50% and colonization prevalence was 40%, or decolonization was 75% successful and colonization prevalence was 20%. The intervention was never cost-effective using PCR-based laboratory methods. The cost of agar versus PCR and their respective sensitivities and specificities, as well as the probability of successful decolonization, were important drivers of the economic and health impacts of preoperative screening and decolonization of pregnant women. The number needed to screen ranged from 21 to 2294, depending on colonization prevalence, laboratory techniques used, and the probability of successful decolonization.

**Conclusions**—Despite high rates of cesarean delivery, presurgical screening of pregnant women for *S aureus* and decolonization of carriers is unlikely to be cost-effective under prevailing epidemiologic circumstances.

*Staphylococcus aureus* surgical site infections (SSIs) are associated with substantial morbidity among women who undergo cesarean delivery, resulting in increased postoperative length of stay, increased risk of readmission, and high medical costs.<sup>1</sup> The increasing incidence of postsurgical wound infections has paralleled a rise in the cesarean

**Address correspondence to:** Bruce Y. Lee, MD, MBA, Public Health Computational and Operations Research, University of Pittsburgh, 200 Meyran Ave, Ste 200, Pittsburgh, PA 15213. BYL1@pitt.edu.

**Author Disclosures:** The authors (BYL, AEW, EAM, SMM, ANA, YS, RHB) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.

**Authorship Information:** Concept and design (AEW, YS, RHB); acquisition of data (AEW, EAM, YS, RHB); analysis and interpretation of data (AEW, EAM, SMM, ANA, YS, RHB); drafting of the manuscript (AEW, EAM, SMM, ANA, YS, RHB); critical revision of the manuscript for important intellectual content (SMM, RHB); statistical analysis (AEW, EAM, ANA); obtaining funding (BYL); administrative, technical, or logistic support (BYL, RHB); and supervision (BYL, RHB).

delivery rate. As many as 20% of women who deliver by cesarean are affected by an SSI, and *S aureus* is the causative agent implicated in 25% to 50% of puerperal infections.<sup>1–8</sup>

Up to 35% of Americans are chronic or intermittent carriers of *S aureus*, with higher rates observed among individuals with risk factors for colonization such as healthcare exposure, recent antibiotic use, immune system compromise, and chronic health conditions such as diabetes and hepatitis.<sup>5,9–12</sup> Previous studies have shown that preoperative *S aureus* screening and subsequent decolonization of carriers may lessen rates of SSIs among other surgical populations.<sup>13–17</sup> These measures may be of benefit in the setting of planned cesarean delivery, but formal studies to determine the safety and efficacy of this practice have not yet concluded.<sup>18</sup> The economic value of implementing this strategy among pregnant women, who tend to be younger and healthier than many patients with healthcare-associated *S aureus* infections, has also not been studied.

To address this issue, we developed a computer simulation model to estimate the cost-effectiveness and health impact of routine preoperative *S aureus* screening and decolonization for women undergoing planned cesarean delivery.

## MATERIALS AND METHODS

This study was exempted by the University of Pittsburgh Institutional Review Board. Our stochastic decision analytic model, developed using TreeAge Pro 2009 (TreeAge Software, Williamstown, Massachusetts), addressed the decision of whether to screen women for *S aureus* colonization and decolonize carriers before planned cesarean delivery. Analyses assumed a third-party payer perspective (accounting for only the direct costs of illness) and time horizon for outcomes equal to the duration of the puerperal period, or approximately 1 month postdelivery. The 1-month timeline was utilized as a reasonable average based on clinical experience. Because wound infections vary in severity (some are minor, requiring fewer than 28 days of home health treatment, and some are major, requiring 1–2 months of treatment), we used 1 month as an average. The model assumed that the large majority of the impact on the woman's quality of life and costs would take place within this time period.

Figure 1 depicts the general structure of the model. At baseline, women were 27.1 years old (the median age at pregnancy in the United States) and preparing to undergo a planned cesarean delivery with standard antibiotic prophylaxis.<sup>19</sup> Screening was assumed to occur alongside testing for Group B streptococcus at routine 35- to 37-week prenatal visits. This assumption was based on the rationale for Group B streptococcus screening at the same gestational age; colonization with *S aureus* can be transient, so screening should be conducted as close to delivery as possible to serve as a reliable proxy of colonization status at that time.<sup>2,9</sup>

The probability of a woman screening positive was influenced by the *S aureus* colonization prevalence and the sensitivity and specificity of the laboratory technique used, either agar culture or polymerase chain reaction (PCR). All women with a positive test result, regardless of true colonization status (eg, true and false positive), received a preoperative decolonization regimen of twice-daily intranasal mupirocin ointment and daily chlorhexidine gluconate washes for 5 days.<sup>15</sup> This regimen is generally considered safe—reported side effects are minor (eg, nasal itching and discomfort, skin irritation)—and assumed not to result in a quality-adjusted life-year (QALY) decrement.<sup>15,16,20</sup>

When successful, decolonization was assumed to mitigate the risk of post-cesarean infection for the duration of the puerperal period. Women colonized with *S aureus* were assumed to be 3 to 5 times more likely to experience staphylococcal post-operative wound infection than their noncolonized counterparts, consistent with studies among other surgical

populations (likeliest value for colonized women: 9%, range: 4%–20%; likeliest value for noncolonized women: 2.25%, range: 0.80%–6.67%).<sup>2,15,21–24</sup>

Women who experienced a post-cesarean wound infection received empiric antibiotic treatment for methicillin-susceptible *S aureus* (MSSA) until laboratory results were available. Identification of methicillin-resistant *S aureus* (MRSA) resulted in a transition to MRSA-appropriate antibiotic coverage for 7 to 14 days, while MSSA infection was treated with a 7-day course of antibiotics.<sup>25</sup> Cesarean wound infection carried a risk of hospitalization and wound-opening procedure in both the inpatient and outpatient settings, and 50% of women who underwent a wound-opening procedure were assumed to receive subsequent home healthcare.

Data inputs were derived from a variety of sources of various design and quality, including large-scale national databases, prior studies, and literature review (where available); the remainder were assumptions based on experience at Magee-Womens Hospital, a large, university-based academic women's hospital in Pittsburgh, Pennsylvania, that performs approximately 10,000 deliveries per year (Table 1). Inpatient stay cost and duration data came from the Healthcare Cost and Utilization Project's Nationwide Inpatient Sample, a longitudinal database of inpatient hospital stay data maintained by the Agency for Healthcare Research and Quality.<sup>26,27</sup> Pharmaceutical costs were set equivalent to the national wholesale price listed in the Red Book.<sup>28</sup> Procedure and laboratory cost data were based on the Centers for Medicare & Medicaid Services reimbursement algorithm National Limitation Amount.<sup>29,30</sup> A 3% discount rate was applied to all costs and utility values, as recommended by the Panel on Cost-Effectiveness in Health and Medicine.<sup>37</sup>

Healthy pregnant women accrued an age-adjusted 0.92 QALY per year of life and a projected life expectancy QALY estimate of 43.96.<sup>38</sup> Women who developed a wound infection were ascribed a QALY weight of 0.6 for the duration of an inpatient stay, if any, and 0.7 for treatment as an outpatient. Given the paucity of data available from studies of pregnant women, these QALY values were drawn from a cost-effectiveness analysis of appendectomy wounds and were likely conservative estimates of the detriment attributable to a cesarean wound infection.<sup>31</sup> QALY decrements were attributed for the duration of antibiotic treatment, or 7 to 14 days for an MRSA infection and 7 days for an MSSA infection. Infected wounds that required opening accrued an additional 7 days, and patients who required home health treatment were ascribed 7 extra days of QALY decrements.

Each simulation run consisted of 1000 hypothetical pregnant women who proceeded through the model 1000 times, for a total of 1 million outcomes per simulated scenario. The incremental cost-effectiveness ratio (ICER) of each scenario was calculated using the equation below, and results were interpreted in the context of 2 cost-effectiveness thresholds: \$50,000 per QALY and \$100,000 per QALY.<sup>39</sup>

$$\text{ICER} = \frac{\text{Cost}_{\text{intervention}} - \text{Cost}_{\text{no intervention}}}{\text{Effectiveness}_{\text{intervention}} - \text{Effectiveness}_{\text{no intervention}}}$$

The number needed to screen (NNS), or the number of women who would need to be screened to prevent 1 post-cesarean wound infection, regardless of true colonization status or decolonization treatment rendered, was calculated as follows:

$$\text{NNS} = \frac{\text{Total number of women}}{\text{Infections}_{\text{no intervention group}} - \text{Infections}_{\text{intervention group}}}$$

Probabilistic sensitivity analyses simultaneously varied all parameters throughout the ranges listed in Table 1. Additional sensitivity analyses explored key variables and those with the greatest uncertainty/variability. We systematically explored the effect of varying *S aureus* colonization prevalence from 1% to 50%, in order to capture the variation that may occur based on geographic location, individual risk factors such as healthcare exposure or recent antibiotic use, and body site swabbed (eg, anterior nares vs groin). The probability of successful decolonization was varied across the range of 0% to 90% to account for factors such as differing anatomical colonization site(s), decolonization regimen efficacy, local antimicrobial resistance patterns, and patient compliance. The laboratory techniques used for screening and wound isolate identification were also explored in the following combinations (screening-wound isolate): agar-agar, PCR-agar, and PCR-PCR to account for variation in the cost, availability, and turnaround time of these diagnostics. Finally, we varied the costs associated with hospitalization ( $\pm$  \$1000).

## RESULTS

Table 2 presents ICER values (dollars per QALY) for a variety of colonization prevalence and decolonization success rate scenarios. The combination of agar-based screening and wound culture yielded the lowest ICER values across all decolonization success and colonization prevalence scenarios. ICER values were driven by low incremental effectiveness values; even when the incremental costs were low (\$3), the gain in QALYs due to screening were minute (range: 0.000001 to 0.00307) for all scenarios. When ICER values below \$50,000 to \$100,000 per QALY were considered cost-effective, the intervention was favorable when the probability of decolonization success was 50% and the colonization prevalence was 40%, decolonization was 75% successful and colonization prevalence was 20%, or the decolonization success rate was 90% and the colonization prevalence was 20%. Exploratory analyses of colonization prevalence >50% revealed that the testing scenario with a pairing of agar-agar became an economically dominant intervention (less costly and more effective than no testing or decolonization) when the probability of decolonization success was 75% and the colonization prevalence was 95%, or the probability of successful decolonization was 90% and the colonization prevalence was 75%. Varying the cost of hospitalization did not significantly change our results. For the agar-agar pairing, ICER values were \$5897 per QALY (hospitalization cost + \$1000) and \$13,220 (hospitalization cost – \$1000) at a 90% decolonization success rate and 50% colonization rate.

The use of PCR for screening and agar for wound cultures led to higher ICER values than the agar-agar screening and culture combination. The intervention was never found to be cost-effective (ICER values \$50,000 to \$100,000 per QALY) when the probability of decolonization success was 90% and the probability of colonization with *S aureus* was 50%. Exploratory analyses of colonization prevalence >50% revealed that the intervention was cost-effective when the probability of decolonization success was 75% and colonization prevalence was 80%, or decolonization was 90% effective and colonization prevalence was 95%. The pairing of PCR and agar was never economically dominant. The combination of PCR-PCR for screening and wound isolates yielded the highest ICER values across all scenarios; this combination was never found to be cost-effective if the probability of decolonization success was 90% and the *S aureus* colonization prevalence was 50%, and was never economically dominant in any scenario, even if colonization prevalence was 100%.

The mean NNS to prevent 1 post-cesarean wound infection (regardless of true colonization status or decolonization treatment rendered) for each of the 3 pairings of laboratory methods is shown in Figure 2. A 25% probability of decolonization success was associated with the

highest NNS values across all levels of *S aureus* colonization prevalence. The NNS was 2294 for the agar-agar pairing given 1% colonization prevalence and 25% probability of successful decolonization, and an NNS of 72 was observed for the agar-agar pairing given 50% colonization prevalence and a 25% probability of decolonization success. NNS values demonstrated similar decline for 50%, 75%, and 90% probabilities of successful decolonization. When colonization prevalence was 25% and the probability of successful decolonization was fixed at 25%, 50%, 75%, or 90%, the NNS was approximately equal for all 3 pairings.

## DISCUSSION

These results suggest that routine preoperative *S aureus* screening and decolonization of carriers for women undergoing planned cesarean is rarely a cost-effective intervention, and only for the pairing of agar-based testing and agar-based wound culture. In addition, the intervention is unlikely to be cost saving given the current epidemiologic circumstances of *S aureus* colonization in the United States. The prevalence of *S aureus* carriage among pregnant women has been reported to range from 5% to 29%, well below the 75% (or greater) value needed to yield cost savings in this study.<sup>5,9,40–42</sup> The cost of implementing routine surveillance and decolonization of *S aureus* carriers outweighs the potential cost savings from preventing morbidity, mortality, and increased hospital lengths of stay associated with post-cesarean *S aureus* wound infections.

There is some discordance in the rank order of the optimal pairing strategy when comparing ICER with NNS under the same circumstances (eg, probability of successful decolonization and colonization prevalence). This is likely a result of the cost difference between agar culture and PCR laboratory techniques, and the respective predictive values of agar culture and PCR for the detection of *S aureus*. Given the moderate *S aureus* colonization prevalence and relatively low incidence of post-cesarean infection in this population, cost of the intervention is a primary driver of the results. The impact of the higher sensitivity and specificity of PCR versus agar is best seen in the NNS values. Because correct ascertainment of colonization status is more likely with PCR-based screening, colonized women are more likely to get potentially beneficial presurgical decolonization treatment and there is a low probability that a presurgical decolonization regimen will be prescribed to a non-colonized woman. As a result, PCR-based screening reduces the cost and risk of unnecessary treatment, side effects, and the development of antimicrobial resistance.

Data on the short-term effectiveness of various decolonization regimens, especially for pregnant women, are equivocal.<sup>15–17</sup> There is a need for future studies, particularly well-designed randomized controlled trials, to better establish the efficacy of various decolonization regimens among this population. The assumption that pregnant women colonized with *S aureus* are at an increased risk of infection is based on the increased risk of *S aureus* infections seen among other surgical patients. The validity of this extension is unknown given the paucity of relevant data in the literature; additional studies of the risk of *S aureus* colonization (in the nares and other sites such as the perineum and vagina) on postpartum and post-cesarean infection would be a valuable addition to the body of knowledge.

Delivery by cesarean has become the most common major surgery among women in the United States each year. The US cesarean delivery rate (both primary and repeat procedures) has increased more than 50% since 1996 and reached an all-time high of 32.3% in 2008.<sup>43</sup> Historically, cesarean rates have increased with increasing age, but in recent years the rate has increased substantially across all maternal age and risk groups, race/ethnic groups, gestational ages, and geographic locations.<sup>44</sup> The rapidly increasing rate of cesarean

delivery, coupled with the fact that it is major abdominal surgery, has spurred questions about the clinical and nonmedical factors contributing to the upward trend.<sup>45</sup> An operative procedure of this magnitude is not without risk to mother and baby; cesarean deliveries have been associated with increased rates of operative complications, maternal rehospitalization, and neonatal intensive-care unit admission for neonates.<sup>45</sup>

Our analyses outlined the potential economic impact of implementing a routine pre-cesarean screening and decolonization program under a variety of circumstances. This study may be of interest to clinicians, infection control specialists, hospital administrators, and insurers who make complex decisions regarding the finance and practice of clinical care. As with any cost-effectiveness analysis, our findings are only intended to serve as informative evidence for the decision-making process. A sound decision is based on multiple factors such as clinical experience; budgetary constraints; competition for physical, personnel, and monetary resources; and disease epidemiology.

Our study may have underestimated the potential benefit of implementing a screening and decolonization strategy. Precesarean screening and decolonization could mitigate the risk of developing *S aureus* mastitis, which affects 2% to 33% of breast-feeding women.<sup>7</sup> It could also limit transmission of *S aureus* from mothers to their newborns, thereby minimizing infections in a vulnerable population with immature immune systems. Additionally, some women may require a repeat surgical procedure and thus may benefit from the decolonization intervention. Also, we limited our outcomes to the puerperal period; however, some women may have impacts lasting longer than 1 month. We did not attempt to quantify the impact of decreased *S aureus* colonization in the population or the subsequent epidemiologic impact. Finally, routine surveillance could provide important data on the epidemiology of *S aureus* among the population of pregnant women.

Overall, our study findings indicate that screening pregnant women for *S aureus* with decolonization before cesarean delivery is not a cost-effective intervention under prevailing epidemiologic circumstances, despite the increasing rate of delivery by cesarean. Future studies are needed to ascertain the safety and efficacy of various decolonization regimens for this population, as is delineation of the risk of postpartum and post-cesarean infection attributable to *S aureus* colonization at different anatomical sites such as the nares, vagina, and perineum.

## Acknowledgments

**Funding Source:** This work was supported in part by the National Institutes of Health National Institute of General Medical Sciences Models of Infectious Disease Agent Study research network through grant 1U54GM088491-0109, the US Centers for Disease Control and Prevention through grant 5P01HK00086-02, the National Library of Medicine through grant 5R01LM009132-02, and the Pennsylvania Department of Health.

## REFERENCES

1. Killian CA, Graffunder EM, Vinciguerra TJ, Venezia RA. Risk factors for surgical-site infections following cesarean section. *Infect Control Hosp Epidemiol*. 2001; 22(10):613–617. [PubMed: 11776346]
2. Gray J, Patwardhan SC, Martin W. Methicillin-resistant *Staphylococcus aureus* screening in obstetrics: a review. *J Hosp Infect*. 2010; 75(2):89–92. [PubMed: 20381905]
3. Yokoe DS, Christiansen CL, Johnson R, et al. Epidemiology of and surveillance for postpartum infections. *Emerg Infect Dis*. 2001; 7(5):837–841. [PubMed: 11747696]
4. Beigi RH, Bunge K, Song Y, Lee BY. Epidemiologic and economic effect of methicillin-resistant *Staphylococcus aureus* in obstetrics. *Obstet Gynecol*. 2009; 113(5):983–991. [PubMed: 19384112]

5. Beigi R, Hanrahan J. *Staphylococcus aureus* and MRSA colonization rates among gravidas admitted to labor and delivery: a pilot study. *Infect Dis Obstet Gynecol*. 2007; 2007:70876. [PubMed: 18273405]
6. Henderson E, Love EJ. Incidence of hospital-acquired infections associated with caesarean section. *J Hosp Infect*. 1995; 29(4):245–255. [PubMed: 7658004]
7. Barbosa-Cesnik C, Schwartz K, Foxman B. Lactation mastitis. *JAMA*. 2003; 289(13):1609–1612. [PubMed: 12672715]
8. Sweet, RL.; Gibbs, RS. *Infectious Diseases of the Female Genital Tract*. 4th ed.. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
9. Chen KT, Huard RC, Della-Latta P, Saiman L. Prevalence of methicillin-sensitive and methicillin-resistant *Staphylococcus aureus* in pregnant women. *Obstet Gynecol*. 2006; 108((3, pt 1)):482–487. [PubMed: 16946204]
10. Anderson DJ, Sexton DJ, Kanafani ZA, Auten G, Kaye KS. Severe surgical site infection in community hospitals: epidemiology, key procedures, and the changing prevalence of methicillin-resistant *Staphylococcus aureus*. *Infect Control Hosp Epidemiol*. 2007; 28(9):1047–1053. [PubMed: 17932825]
11. Wilcox MH, Hall J, Pike H, et al. Use of perioperative mupirocin to prevent methicillin-resistant *Staphylococcus aureus* (MRSA) orthopaedic surgical site infections. *J Hosp Infect*. 2003; 54(3): 196–201. [PubMed: 12855234]
12. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with *Staphylococcus aureus* in the United States, 2001–2004. *J Infect Dis*. 2008; 197(9):1226–1234. [PubMed: 18422434]
13. Trautmann M, Stecher J, Hemmer W, Luz K, Panknin HT. Intranasal mupirocin prophylaxis in elective surgery: a review of published studies. *Chemotherapy*. 2008; 54(1):9–16. [PubMed: 18063862]
14. Coates T, Bax R, Coates A. Nasal decolonization of *Staphylococcus aureus* with mupirocin: strengths, weaknesses and future prospects. *J Antimicrob Chemother*. 2009; 64(1):9–15. [PubMed: 19451132]
15. Bode LG, Kluytmans JA, Wertheim HF, et al. Preventing surgical site infections in nasal carriers of *Staphylococcus aureus*. *N Engl J Med*. 2010; 362(1):9–17. [PubMed: 20054045]
16. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane Database Syst Rev*. 2008; (4):CD006216. [PubMed: 18843708]
17. van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. Intranasal mupirocin for reduction of *Staphylococcus aureus* infections in surgical patients with nasal carriage: a systematic review. *J Antimicrob Chemother*. 2008; 61(2):254–261. [PubMed: 18174201]
18. Shrem, G. [Accessed July 1, 2010] Effect of Intranasal Mupirocin on Rate of *Staphylococcus aureus* Surgical Site Infection Following Cesarean Sections. *Clinicaltrials.gov* identifier: NCT01152593. Jun 28. 2010 <http://www.clinicaltrials.gov/ct2/results?term=NCT01152593>
19. Mathews TJ, Hamilton BE. Mean age of mother, 1970–2000. *Natl Vital Stat Rep*. 2002; 51(1):1–13. [PubMed: 12564162]
20. Perl TM, Cullen JJ, Wenzel RP, et al. Mupirocin And The Risk Of *Staphylococcus Aureus* Study Team. Intranasal mupirocin to prevent postoperative *Staphylococcus aureus* infections. *N Engl J Med*. 2002; 346(24):1871–1877. [PubMed: 12063371]
21. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of *Staphylococcus aureus*: epidemiology, underlying mechanisms, and associated risks. *Clin Microbiol Rev*. 1997; 10(3):505–520. [PubMed: 9227864]
22. Perl TM, Golub JE. New approaches to reduce *Staphylococcus aureus* nosocomial infection rates: treating *S. aureus* nasal carriage. *Ann Pharmacother*. 1998; 32(1):S7–S16. [PubMed: 9475834]
23. Simor AE, Daneman N. *Staphylococcus aureus* decolonization as a prevention strategy. *Infect Dis Clin North Am*. 2009; 23(1):133–151. [PubMed: 19135919]
24. Wenzel RP, Perl TM. The significance of nasal carriage of *Staphylococcus aureus* and the incidence of postoperative wound infection. *J Hosp Infect*. 1995; 31(1):13–24. [PubMed: 7499817]


25. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. Clin Infect Dis. 2011; 52(3):285–292. [PubMed: 21217178]
26. Agency for Healthcare Research and Quality. [Accessed June 23, 2010] Introduction to the HCUP Nationwide Inpatient Sample (NIS)2008. May. 2010 [http://www.hcup-us.ahrq.gov/db/nation/nis/NIS\\_2008\\_INTRODUCTION.pdf](http://www.hcup-us.ahrq.gov/db/nation/nis/NIS_2008_INTRODUCTION.pdf).
27. Agency for Healthcare Research and Quality. [Accessed September 6, 2011] HCUPnet. Healthcare Cost and Utilization Project (HCUP). 2010. <http://hcupnet.ahrq.gov/>.
28. Physicians' Desk Reference Inc. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Reuters; 2009.
29. Centers for Medicare & Medicaid Services. [Accessed September 6, 2011] Clinical Laboratory Fee Schedule. 2010. <https://www.cms.gov/ClinicalLabFeeSched/>.
30. Centers for Medicare & Medicaid Services. [Accessed September 6, 2011] Physician Fee Schedule look-up. 2010. <https://www.cms.gov/apps/physician-fee-schedule/>.
31. Brasel KJ, Borgstrom DC, Weigelt JA. Cost-utility analysis of contaminated appendectomy wounds. J Am Coll Surg. 1997; 184(1):23–30. [PubMed: 8989296]
32. Bailit JL, Landon MB, Lai Y, et al. Maternal-fetal medicine units network cesarean registry: impact of shift change on cesarean complications. Am J Obstet Gynecol. 2008; 198(2):173.e1–.e5.
33. Andriesse GI, van Rijen M, Bogaers D, Bergmans AM, Kluytmans JA. Comparison of two PCR-based methods and conventional culture for the detection of nasal carriage of *Staphylococcus aureus* in pre-operative patients. Eur J Clin Microbiol Infect Dis. 2009; 28(10):1223–1226. [PubMed: 19562391]
34. Keene A, Vavagiakis P, Lee MH, et al. *Staphylococcus aureus* colonization and the risk of infection in critically ill patients. Infect Control Hosp Epidemiol. 2005; 26(7):622–628. [PubMed: 16092742]
35. Paule SM, Pasquariello AC, Hacek DM, et al. Direct detection of *Staphylococcus aureus* from adult and neonate nasal swab specimens using real-time polymerase chain reaction. J Mol Diagn. 2004; 6(3):191–196. [PubMed: 15269294]
36. Shrestha NK, Shermock KM, Gordon SM, et al. Predictive value and cost-effectiveness analysis of a rapid polymerase chain reaction for preoperative detection of nasal carriage of *Staphylococcus aureus*. Infect Control Hosp Epidemiol. 2003; 24(5):327–333. [PubMed: 12785405]
37. Gold, MR.; Russel, LB.; Siegel, JE.; Weinstein, MC., editors. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
38. Wilmoth, J.; Shkolnikov, V. The Human Mortality Database. Berkeley: University of California; 2010. <http://www.mortality.org/>. [Accessed September 6, 2011]
39. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000; 20(3):332–342. [PubMed: 10929856]
40. Top KA, Huard RC, Fox Z, et al. Trends in methicillin-resistant *Staphylococcus aureus* anovaginal colonization in pregnant women in 2005 vs 2009. J Clin Microbiol. 2010; 48(10):3675–3680. [PubMed: 20686089]
41. Andrews JI, Fleener DK, Messer SA, Kroeger JS, Diekema DJ. Screening for *Staphylococcus aureus* carriage in pregnancy: usefulness of novel sampling and culture strategies. Am J Obstet Gynecol. 2009; 201(4):396.e1–5. [PubMed: 19716114]
42. Creech CB, Litzner B, Talbot TR, Schaffner W. Frequency of detection of methicillin-resistant *Staphylococcus aureus* from rectovaginal swabs in pregnant women. Am J Infect Control. 2010; 38(1):72–74. [PubMed: 19836855]
43. Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary data for 2008. National Vital Stat Rep. Apr 6; 2010 58(16):1–17. [http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58\\_16.pdf](http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_16.pdf).
44. MacDorman MF, Menacker F, Declercq E. Cesarean birth in the United States: epidemiology, trends, and outcomes. Clin Perinatol. 2008; 35(2):293–307. [PubMed: 18456070]
45. Menacker F, Hamilton BE. Recent trends in cesarean delivery in the United States. NCHS Data Brief. 2010; (35):1–8. [PubMed: 20334736]

### Take-Away Points

Screening pregnant women for *Staphylococcus aureus* before cesarean delivery is unlikely to be cost-effective under currently prevailing epidemiologic circumstances in the United States.


The results were similar for analyses with cost-effectiveness thresholds of \$50,000 per quality-adjusted life-year (QALY) and \$100,000 per QALY

Additional studies are needed to ascertain the safety and efficacy of decolonizing pregnant women, as well as the risk of post-cesarean infection attributable to *S aureus*.



**Figure 1. General Model Structure**

MSSA indicates methicillin-susceptible *Staphylococcus aureus*; OR, operating room; SSI, surgical site infection; tx, treatment.



**Figure 2. Number Needed to Screen to Prevent 1 Post-cesarean Wound Infection**  
PCR indicates polymerase chain reaction.

Table 1

## Model Data Inputs

| Variable  | Distribution Type | Mean, <sup>a</sup> Median, <sup>b</sup> or Mode <sup>c</sup> | Standard Deviation or Range | Reference               |
|---|-------------------|--|-----------------------------|-------------------------|
| <b>Patient characteristics</b>                      |                   |  |                             |                         |
| Age of pregnant women, y                            | —                 | 27.1 <sup>b</sup>  | —                           | 19                      |
| QALY value: inpatient treatment of wound infection  | —                 | 0.60   | —                           | 31                      |
| QALY value: outpatient treatment of wound infection | —                 | 0.70   | —                           | 31                      |
| <b>Costs, \$</b>                                    |                   |  |                             |                         |
| <b>Laboratory</b>                                   |                   |  |                             |                         |
| Agar screening/wound culture                        | —                 | 12.34 <sup>a</sup>   | 0.95                        | 29                      |
| PCR screening/wound culture                         | —                 | 50.27 <sup>a</sup>   | 5.53                        | 29                      |
| <b>Pharmaceuticals</b>                              |                   |  |                             |                         |
| Cephalexin (per day)                                |                   | 7.47 <sup>a</sup>  | 5.71                        | 28                      |
| Chlorhexidine (full course)                         |                   | 6.44 <sup>a</sup>  | 2.88                        | 28                      |
| Mupirocin (full course)                             |                   | 8.07 <sup>a</sup>  | 1.38                        | 28                      |
| Sulfamethoxazole-trimethoprim (per day)             |                   | 3.29 <sup>a</sup>  | 1.27                        | 28                      |
| Unasyn (per day)                                    |                   | 65.25 <sup>a</sup>   | 14.80                       | 28                      |
| Vancomycin (per day)                                |                   | 31.49 <sup>a</sup>   | 16.84                       | 28                      |
| <b>Hospitalization</b>                              |                   |  |                             |                         |
| Maternal hospitalization for wound infection        |                   | 6110.53 <sup>a</sup>   | 394.47                      | 26,27                   |
| <b>Procedures and supplies</b>                      |                   |  |                             |                         |
| Home health supplies (per week)                     |                   | 34.78 <sup>a</sup>   | 6.96                        | Assumption <sup>d</sup> |
| Home health visitation (per week)                   |                   | 469.75 <sup>a</sup>  | 93.91                       | Assumption <sup>d</sup> |
| Open wound incision in outpatient setting           |                   | 50.41 <sup>a</sup>   | 4.55                        | 30                      |
| Open wound incision in OR                           |                   | 735.18 <sup>a</sup>  | 45.54                       | 30                      |
| Open wound incision on ward                         |                   | 74.89 <sup>a</sup>   | 7.20                        | 30                      |
| <b>Duration, days</b>                               |                   |  |                             |                         |
| Antibiotic treatment for MRSA                       | —                 | 7–14   | —                           | 25                      |
| Antibiotic treatment for MSSA                       | —                 | 7  | —                           | 25                      |
| Empiric antibiotic treatment                        |                   | 1.5 <sup>c</sup>   | 1.0–2.0                     | Assumption <sup>d</sup> |
| Home health treatment                               |                   | 28 <sup>c</sup>  | 14–42                       | Assumption <sup>d</sup> |
| Maternal hospitalization for wound infection        |                   | 3.8 <sup>a</sup>   | 0.1                         | 26,27                   |
| <b>Probability, %</b>                               |                   |  |                             |                         |
| <b>Conditions and procedures</b>                    |                   |  |                             |                         |
| Wound infection if <i>S aureus</i> colonized        |                   | 9  | 4–20                        | 2,15,21–24              |
| Wound infection if not <i>S aureus</i> colonized    |                   | 2.25   | 0.8–6.67                    | 2,15,21–24              |

| Variable  | Distribution Type            | Mean, <sup>a</sup> Median, <sup>b</sup> or Mode <sup>c</sup> | Standard Deviation or Range | Reference                   |
|---|------------------------------|--|-----------------------------|-----------------------------|
| Hospitalization (given wound infection)                   |                              | 2.0 <sup>c</sup>   | 1.5–2.5                     | 32, Assumption <sup>d</sup> |
| Inpatient wound-opening procedure (given hospitalization) |                              | 95 <sup>c</sup>  | 91–99                       | Assumption <sup>d</sup>     |
| Wound opening in OR                                       |                              | 15 <sup>c</sup>  | 0–36                        | Assumption <sup>d</sup>     |
| Wound opening on ward                                     |                              | 85 <sup>c</sup>  | 64–1                        | Assumption <sup>d</sup>     |
| Outpatient wound-opening procedure                        |                              | 20   | 5–40                        | Assumption <sup>d</sup>     |
| Home health after wound opening                           | —                            | 75   | —                           | Assumption <sup>d</sup>     |
| Home health after outpatient wound opening                | —                            | 25   | —                           | Assumption <sup>d</sup>     |
| <b>Laboratory</b>   |                              |  |                             |                             |
| Agar culture sensitivity                                  |                              | 90   | 95.5–100                    | 33–36                       |
| Agar culture specificity                                  |                              | 95   | 97.5–100                    | 33–36                       |
| PCR sensitivity   |                              | 97   | 98.125–100                  | 33–36                       |
| PCR specificity   |                              | 95.5   | 98.34–100                   | 33–36                       |
| <b>Sensitivity analyses</b>                               | <b>Values</b>                |  | <b>Source</b>               |                             |
| Probability of colonization                               | 1%–50% (by increments of 5%) |  | Assumption                  |                             |
| Probability of successful decolonization                  | 25%, 50%, 75%, 90%           |  | Assumption                  |                             |
| Laboratory technique (screening/wound isolate)            | Agar-agar, PCR-agar, PCR-PCR |  | Assumption                  |                             |

MRSA indicates methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-susceptible *Staphylococcus aureus*; OR, operating room; PCR, polymerase chain reaction; QALY, quality-adjusted life-year.

<sup>a</sup>Mean value.

<sup>b</sup>Median value.

<sup>c</sup>Mode value.

<sup>d</sup>Assumption based on experience at Magee-Womens Hospital.

Incremental Cost-Effectiveness Ratios for Maternal *Staphylococcus aureus* Screening and Decolonization Before Cesarean Delivery<sup>a</sup>

Table 2

| Screening/Wound Culture Method                   | ICER by Probability of <i>Staphylococcus aureus</i> Colonization, \$/QALY |           |           |                     |                     |                     |
|--|---|-----------|-----------|---------------------|---------------------|---------------------|
|  | 1%  | 5%        | 10%       | 20%                 | 30%                 | 50%                 |
| <b>25% Probability of decolonization success</b> |   |           |           |                     |                     |                     |
| Agar/agar  | 10,631,077  | 1,313,767 | 922,940   | 402,799             | 283,477             | 179,303             |
| PCR/agar   | 18,244,123  | 5,085,743 | 3,410,549 | 1,360,614           | 951,692             | 607,422             |
| PCR/PCR  | 23,128,146  | 5,259,576 | 2,705,445 | 1,443,178           | 995,366             | 649,926             |
| <b>50% Probability of decolonization success</b> |   |           |           |                     |                     |                     |
| Agar/agar  | 3,942,569   | 869,499   | 344,783   | 184,171             | 110,492             | <b>79,069 (C-E)</b> |
| PCR/agar   | 12,506,785  | 2,611,239 | 1,510,744 | 706,479             | 494,562             | 358,580             |
| PCR/PCR  | 8,643,593   | 2,501,542 | 1,501,343 | 761,849             | 481,436             | 341,625             |
| <b>75% Probability of decolonization success</b> |   |           |           |                     |                     |                     |
| Agar/agar  | 1,739,106   | 486,301   | 195,540   | <b>91,616 (C-E)</b> | <b>55,068 (C-E)</b> | <b>25,121 (C-E)</b> |
| PCR/agar   | 7,751,050   | 2,134,213 | 960,480   | 478,422             | 309,852             | 217,078             |
| PCR/PCR  | 8,488,401   | 1,791,167 | 963,867   | 468,356             | 299,476             | 212,607             |
| <b>90% Probability of decolonization success</b> |   |           |           |                     |                     |                     |
| Agar/agar  | 1,512,341   | 434,147   | 174,660   | <b>69,714 (C-E)</b> | <b>37,634 (C-E)</b> | <b>9993 (C-E)</b>   |
| PCR/agar   | 9,726,700   | 1,700,280 | 804,716   | 367,620             | 245,711             | 172,807             |
| PCR/PCR  | 14,427,708  | 1,482,124 | 776,970   | 377,815             | 230,870             | 165,887             |

ICER indicates incremental cost-effectiveness ratio; PCR, polymerase chain reaction; QALY, quality-adjusted life-year.

<sup>a</sup>Cells with boldface values and delineated by (C–E) indicate scenarios in which the intervention was cost-effective when values below \$50,000 to \$100,000 per QALY were considered cost-effective.